Table 2.
Regular NSAID use by age, gene group and region
| Any NSAID | Ibuprofen | Aspirin | ||||
|---|---|---|---|---|---|---|
| LRRK2-PD | LRRK2-nonPD | LRRK2-PD | LRRK2-nonPD | LRRK2-PD | LRRK2-nonPD | |
| Overall (n, %) | 28 (10.9) | 101 (31.8) | 6 (2.37) | 23 (7.26) | 21 (8.20) | 77 (24.21) |
| Age | ||||||
| <50 | 3 (4.2) | 9 (12.7) | 0 (0.0) | 8 (11.27) | 2 (2.9) | 3 (4.23) |
| 50–59 | 6 (6.7) | 14 (24.1) | 1 (1.12) | 6 (10.34) | 5 (5.6) | 7 (12.07) |
| 60–69 | 14 (20.3) | 32 (37.6) | 4 (5.97) | 4 (4.71) | 10 (14.7) | 25 (29.41) |
| 70–79 | 5 (18.5) | 35 (44.9) | 1 (4.0) | 3 (3.85) | 4 (14.8) | 32 (41.03) |
| >79 | 0 (0.0) | 11 (42.3) | 0 (0.0) | 2 (8.0) | 0 (0.0) | 10 (38.46) |
| Gene group | ||||||
| Pathogenic variants carriers | ||||||
| All | 26 (11.2) | 38 (22.5) | 6 (2.7) | 20 (11.9) | 19 (8.3) | 15 (8.9) |
| G2019S | 24 (12.7) | 31 (24.6) | 6 (3.3) | 18 (14.4) | 17 (9.1) | 12 (9.5) |
| R1441 | 2 (5.4) | 7 (16.3) | 0 (0.0) | 2 (4.7) | 2 (5.6) | 3 (7.0) |
| I2020T | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Risk variant carriers | ||||||
| All | 2 (7.1) | 63 (42.3) | 0 (0.0) | 3 (2.0) | 2 (7.1) | 62 (41.6) |
| G2385R | 2 (8.3) | 33 (36.7) | 0 (0.0) | 1 (1.1) | 2 (8.3) | 33 (36.7) |
| R1628P | 0 (0.0) | 30 (50.8) | 0 (0.0) | 2 (3.4) | 0 (0.0) | 29 (49.2) |
| Region | ||||||
| Asia | 2 (6.3) | 63 (42.3) | 0 (0.0) | 3 (2.0) | 2 (6.3) | 62 (41.6) |
| Australia | 1 (12.5) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (12.5) | 0 (0.0) |
| Europe | 10 (6.0) | 18 (17.0) | 1 (0.6) | 11 (10.5) | 9 (5.4) | 4 (3.8) |
| North America | 15 (36.6) | 20 (32.8) | 5 (12.8) | 9 (14.8) | 9 (22.5) | 11 (18.0) |